Salsalate Improves Glycemia and Inflammatory Parameters in Obese

Total Page:16

File Type:pdf, Size:1020Kb

Salsalate Improves Glycemia and Inflammatory Parameters in Obese Emerging Treatments and Technologies ORIGINAL ARTICLE Salsalate Improves Glycemia and Inflammatory Parameters in Obese Young Adults 1,2,3 1,2 AMY FLEISCHMAN, MD, MMSC RAQUEL BERNIER, BS been reinvestigated, and the molecular 1,2 1,2 STEVEN E. SHOELSON, MD, PHD ALLISON B. GOLDFINE, MD target was identified to be the I␬B kinase complex ␤ (IKK␤)/nuclear factor ␬B (NF- ␬B) pathway (8,9), a central integrator of OBJECTIVE — Sedentary lifestyle and a western diet promote subacute-chronic inflamma- proinflammatory signals (2). The thera- tion, obesity, and subsequently dysglycemia. The aim of the current study was to evaluate the peutic potential of high-dose aspirin is efficacy of the anti-inflammatory drug salsalate to improve glycemia by reducing systemic in- limited by bleeding risk. Salsalate, a dimer flammation in obese adults at risk for the development of type 2 diabetes. of salicylic acid, has an established safety profile after decades of use for rheumatic RESEARCH DESIGN AND METHODS — In a double-masked, placebo controlled pain. As a nonacetylated salicylate, sal- trial, we evaluated 20 obese nondiabetic adults at baseline and after 1 month of salsalate or salate is an equipotent inhibitor of NF-␬B placebo. but has a lower bleeding risk than aspirin RESULTS — Compared with placebo, salsalate reduced fasting glucose 13% (P Ͻ 0.002), (10,11). glycemic response after an oral glucose challenge 20% (P Ͻ 0.004), and glycated albumin 17% To our knowledge, this is the first (P Ͻ 0.0003). Although insulin levels were unchanged, fasting and oral glucose tolerance test study to assess metabolic changes with C-peptide levels decreased in the salsalate-treated subjects compared with placebo (P Ͻ 0.03), administration of salicylates to obese in- consistent with improved insulin sensitivity and a known effect of salicylates to inhibit insulin dividuals without diabetes. We hypothe- clearance. Adiponectin increased 57% after salsalate compared with placebo (P Ͻ 0.003). Ad- sized that salicylates administered for 1 ditionally, within the group of salsalate-treated subjects, circulating levels of C-reactive protein month would improve glycemia in obese Ͻ were reduced by 34% (P 0.05). young adults. CONCLUSIONS — This proof-of-principle study demonstrates that salsalate reduces gly- cemia and may improve inflammatory cardiovascular risk indexes in overweight individuals. RESEARCH DESIGN AND These data support the hypothesis that subacute-chronic inflammation contributes to the patho- METHODS — The Joslin Diabetes genesis of obesity-related dysglycemia and that targeting inflammation may provide a therapeu- Center institutional review board ap- tic route for diabetes prevention. proved the double-masked, placebo- controlled study. Written informed Diabetes Care 31:289–294, 2008 consent was obtained. Subjects were Ͻ30 years and obese, with BMI Ն30 kg/m2. besity, occurring at epidemic rates opment of insulin resistance (1,2). Thus, Participants were excluded for recent worldwide, is a major risk factor for targeting the inflammatory pathway may blood donation, change in weight Ͼ5% in O diabetes and cardiovascular dis- be a novel pharmacologic intervention for the preceding 6 months, use of medica- ease. Thus, there is an urgent need for diabetes prevention and treatment. tion known to alter glucose metabolism, effective interventions to prevent diabetes Salicylates are among the most com- acute febrile illness, biochemical evidence in obese populations. The importance of monly used nonsteroidal anti-inflamma- of renal or hepatic dysfunction, aspirin lifestyle modification in obesity and dia- tory drugs. The benefits of salicylates for allergy, history of gastritis or gastrointes- betes is well recognized. However, disap- treatment of diabetes have long been rec- tinal bleeding, or diabetes. Women were pointing long-term results of these ognized (3,4). High doses of the salicylate excluded for pregnancy, lactation, or lack treatments have led to increased interest aspirin (4–7 g/day) improve fasting and of contraception use. in pharmaceutical intervention. Obesity postprandial hyperglycemia in patients Participants were instructed to con- and high-fat western diets activate inflam- with diabetes (5–7). In recent studies, the sume a high-carbohydrate diet (250–300 matory processes, which promote devel- hypoglycemic actions of salicylates have g/day) and abstain from strenuous exer- ●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●● cise for 3 days before evaluations and not to alter dietary or exercise habits during From the 1Harvard Medical School, Boston, Massachusetts; the 2Joslin Diabetes Center, Boston, Massachu- setts; and the 3Children’s Hospital Boston, Boston, Massachusetts. the study. Blood pressure was measured Address correspondence and reprint requests to Allison B. Goldfine, MD, Joslin Diabetes Center, One twice (DINAMAP PRO-100; General Joslin Place, Boston, MA 02215. E-mail: allison.goldfi[email protected]. Electric Healthcare) with the patient su- Received for publication 5 September 2007 and accepted in revised form 18 October 2007. pine for 10 min. Fasting lipids and cyto- Published ahead of print at http://care.diabetesjournals.org on 24 October 2007. DOI: 10.2337/dc07- 1338. Clinical trial reg. no. NCT00258115, clinicaltrials.gov. kines were measured, and oral glucose Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRP, C-reactive protein; tolerance tests (OGTTs) were performed FFA, free fatty acid; HOMA-IR, homeostasis model assessment of insulin resistance; HOMA-IRC-peptide, with glucose, insulin, and C-peptide lev- homeostasis model assessment of insulin resistance calculated using C-peptide; IKK␤,I␬B kinase complex els measured before and 30, 60, 90, and ␤ ␬ ␬ ; NF- B, nuclear factor- B; OGTT, oral glucose tolerance test. 120 min after a 75-g glucose load. All sub- © 2008 by the American Diabetes Association. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby jects were nondiabetic on the basis of marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. American Diabetes Association guidelines DIABETES CARE, VOLUME 31, NUMBER 2, FEBRUARY 2008 289 Salsalate improves glycemia in obesity (12). Insulin resistance was determined Table 1—Baseline subject characteristics using homeostasis model assessment of insulin resistance (HOMA-IR) for insulin Salsalate therapy Placebo and HOMA-IR calculated using C- peptide (HOMA-IRC-peptide), as described Sex (male/female) 1/8 2/9 by the modified formula HOMA-IR Ethnicity (W/H/B/other) 5/3/1 5/1/4/1 C- Ϯ Ϯ peptide ϭ (fasting C-peptide ϫ fasting glu- Age (years) 23.5 1.1 24.1 1.0 cose)/22.5 (13). BMI (kg/m2) 36.3 Ϯ 2.2 38.9 Ϯ 2.5 Subjects were randomly assigned by a Waist circumference (cm) 106 Ϯ 5 116 Ϯ 6 research pharmacist to receive salsalate, Current smoking 3 of 9 2 of 11 4.0 g/day (Caraco Pharmaceutical Labo- Cholesterol (mmol/l) 4.0 Ϯ 0.3 4.6 Ϯ 0.2 ratories, Detroit, MI) divided in two Triglycerides (mmol/l) 1.0 Ϯ 0.1 1.1 Ϯ 0.2 doses, or identical placebo for 4 weeks. Systolic blood pressure 121 Ϯ 4 123 Ϯ 4 Participants and study personnel were Diastolic blood pressure 67 Ϯ 371Ϯ 3 blinded to the treatment assignment. The Fasting glucose (mmol/l) 5.0 Ϯ 0.2 4.8 Ϯ 0.1 starting dose was selected on the basis of 120-min glucose (mmol/l) 6.7 Ϯ 0.4 6.8 Ϯ 0.4 tolerability data in patients with arthritis Data are means Ϯ SEM. There were no significant differences in the baseline characteristics between the (14). A dose-reduction plan was specified salsalate and placebo groups. W, white, non-Hispanic; H, Hispanic; B, African-American. a priori with stepped reductions of 500 mg for symptoms related to salicylate use, such as tinnitus or headache. Compliance min (a), partial enzymatic digestion of al- pants. There were no significant changes was evaluated by salicylate levels. bumin at glycated sites (b), reassessment in weight, systolic or diastolic blood pres- Twenty-seven subjects were enrolled. of albumin (c), and a Ϫ c. sure, or standard lipid profiles in either One subject became ineligible because of group (Table 2). blood donation after screening. Three sub- Statistical analysis jects withdrew consent because of personal The primary end point was change from Glucose metabolism conflicts and were considered noninforma- baseline in glycemic measures between Fasting glucose decreased 13% in the sal- tive; two had been randomly assigned to salsalate and placebo groups. Secondary salate group compared with the placebo placebo and one to salsalate. Three subjects outcomes were also assessed as change group after 1 month (Ϫ0.4 Ϯ 0.2 vs. were withdrawn because of rash. from baseline within group. Data are pre- ϩ0.2 Ϯ 0.1 mmol/l, respectively, P Ͻ sented as mean Ϯ SEM. Unpaired (sal- 0.002) (Fig. 1A, left). The glucose area Assays salate versus placebo) and paired (before under the curve after a 75-g OGTT was Glucose was measured by glucose oxida- versus after treatment) Student’s t tests also significantly reduced in salsalate tion, cholesterol and HDL were measured were performed. Treatment effects were compared with placebo-treated subjects Ϫ by a cholesterol esterase assay, triglycer- determined by calculating percent change (Ϫ130 Ϯ 53 vs. ϩ38 Ϯ 15 mmol ⅐ min 1 Ϫ ides were measured via hydrolysis to glyc- for each participant. Repeated measures ⅐ l 1, P Ͻ 0.004) (Fig. 1A, center). Like- erol and free fatty acids (FFAs) (Beckman and area under the curve analyses were wise, within groups the glycemic re- Synchron CX3 Delta and CX9; Beckman performed to compare response to OGTT sponse to an OGTT improved after Coulter, Brea, CA), and glycohemoglobin before and after treatment. Completer salsalate treatment (repeated-measures was measured by high-performance liq- analysis was prespecified. Multiple re- analysis P Ͻ 0.01) but not placebo (Fig.
Recommended publications
  • Salsalate Tablets, USP 500 Mg and 750 Mg Rx Only
    SALSALATE RX- salsalate tablet, film coated ANDAPharm LLC Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here. ---------- Salsalate Tablets, USP 500 mg and 750 mg Rx Only Cardiovascular Risk NSAIDs may cause an increase risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. (See WARNINGS and CLINICAL TRIALS). Salsalate tablets, USP is contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery (See WARNINGS). Gastrointestinal Risk NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events. (See WARNINGS). DESCRIPTION Salsalate, is a nonsteroidal anti-inflammatory agent for oral administration. Chemically, salsalate (salicylsalicylic acid or 2-hydroxybenzoic acid, 2-carboxyphenyl ester) is a dimer of salicylic acid; its structural formula is shown below. Chemical Structure: Inactive Ingredients: Colloidal Silicon Dioxide, D&C Yellow #10 Aluminum Lake, Hypromellose, Microcrystalline Cellulose, Sodium Starch Glycolate, Stearic Acid, Talc, Titanium Dioxide, Triacetin. CLINICAL PHARMACOLOGY Salsalate is insoluble in acid gastric fluids (<0.1 mg/mL at pH 1.0), but readily soluble in the small intestine where it is partially hydrolyzed to two molecules of salicylic acid.
    [Show full text]
  • Download Product Insert (PDF)
    PRODUCT INFORMATION Salsalate Item No. 11911 CAS Registry No.: 552-94-3 Formal Name: 2-hydroxy-2-carboxyphenyl ester- benzoic acid Synonyms: Nobacid, NSC 49171 O MF: C14H10O5 FW: 258.2 O Purity: ≥98% UV/Vis.: λ: 207, 234, 308 nm O max OH HO Supplied as: A crystalline solid Storage: -20°C Stability: ≥2 years Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis. Laboratory Procedures Salsalate is supplied as a crystalline solid. A stock solution may be made by dissolving the salsalate in the solvent of choice, which should be purged with an inert gas. Salsalate is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of salsalate in these solvents is approximately 3, 5, and 14 mg/ml, respectively. Salsalate is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, salsalate should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Salsalate has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day. Description Salsalate is a non-steroidal anti-inflammatory drug (NSAID) and prodrug form of salicylic acid.1 It is converted to salicylic acid by hydrolysis. It inhibits prostaglandin E2 (PGE2; Item No. 14010) production in isolated 2 human whole blood stimulated with LPS (IC50 = 39.9 µM). Salsalate (1,000 mg/kg) inhibits weight gain and decreases fasting plasma glucose and insulin levels, as well as decreases plasma cholesterol and triglyceride levels in a mouse model of non-alcoholic steatohepatitis (NASH) induced by a high-fat high-cholesterol diet.3 Formulations containing salsalate have been used in the treatment of pain associated with osteoarthritis and rheumatoid arthritis.
    [Show full text]
  • Salicylate, Diflunisal and Their Metabolites Inhibit CBP/P300 and Exhibit Anticancer Activity
    RESEARCH ARTICLE Salicylate, diflunisal and their metabolites inhibit CBP/p300 and exhibit anticancer activity Kotaro Shirakawa1,2,3,4, Lan Wang5,6, Na Man5,6, Jasna Maksimoska7,8, Alexander W Sorum9, Hyung W Lim1,2, Intelly S Lee1,2, Tadahiro Shimazu1,2, John C Newman1,2, Sebastian Schro¨ der1,2, Melanie Ott1,2, Ronen Marmorstein7,8, Jordan Meier9, Stephen Nimer5,6, Eric Verdin1,2* 1Gladstone Institutes, University of California, San Francisco, United States; 2Department of Medicine, University of California, San Francisco, United States; 3Department of Hematology and Oncology, Kyoto University, Kyoto, Japan; 4Graduate School of Medicine, Kyoto University, Kyoto, Japan; 5University of Miami, Gables, United States; 6Sylvester Comprehensive Cancer Center, Miami, United States; 7Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States; 8Department of Biochemistry and Biophysics, Abramson Family Cancer Research Institute, Philadelphia, United States; 9Chemical Biology Laboratory, National Cancer Institute, Frederick, United States Abstract Salicylate and acetylsalicylic acid are potent and widely used anti-inflammatory drugs. They are thought to exert their therapeutic effects through multiple mechanisms, including the inhibition of cyclo-oxygenases, modulation of NF-kB activity, and direct activation of AMPK. However, the full spectrum of their activities is incompletely understood. Here we show that salicylate specifically inhibits CBP and p300 lysine acetyltransferase activity in vitro by direct *For correspondence: everdin@ competition with acetyl-Coenzyme A at the catalytic site. We used a chemical structure-similarity gladstone.ucsf.edu search to identify another anti-inflammatory drug, diflunisal, that inhibits p300 more potently than salicylate. At concentrations attainable in human plasma after oral administration, both salicylate Competing interests: The and diflunisal blocked the acetylation of lysine residues on histone and non-histone proteins in cells.
    [Show full text]
  • Medications & Supplements to Avoid Before Procedures
    Medications & Supplements to Avoid Before Procedures Do not ingest any brand of aspirin, or any aspirin-containing medication, any MAO inhibiting, or any serotonin medications, for 14 prior to and 14 days after surgery. Disclose every medication, supplement, ​ ​ etc. With Dr. Rau and your anesthesiologist. Aspirin and aspirin-containing products, as well as some supplements and herbals, may inhibit blood clotting and cause difficulties during and after surgery. If you need an aspirin-free fever reducer and pain reliever, take Tylenol. Also, if you smoke, you must refrain for at least a month prior to a month after your surgery date. Smoking significantly reduces your body’s circulation and vascularity, meaning that your tissues won’t receive all the oxygen needed for proper healing. DIET PILLS, FAT LOSS SUPPLEMENTS AND STACKERS: Please stop taking these pills at least 2 ​ weeks before surgery. Many of these pills contain anticoagulants and can seriously impede your body's ability to clot sufficiently, resulting in hemorrhaging. Many of them also contain ephedra and caffeine, which can affect your anesthetic medications. Remember: if you take antibiotics or if you stop oral contraceptive pills for surgery, use an alternative method of birth control. A Aspirin, Advil, Actifed, Acuprin, Addaprin, Alka Seltzer, Alpha Omega (fish oil), Aluprin, Amitriptyline, Anacin, Ansaid, Anodynos, Analval, Anodynos, Ansaid, Argesic, Arthra-G, Arthralgen, Arthropan, Ascodeen, Ascriptin, Aspir-lox, Asperi-mox, Aspirbuf, Aspercin, Aspergum, Axotal, Azdone,
    [Show full text]
  • Arthritis Treatment Comparison Arthritis Treatment Comparison
    ARTHRITIS TREATMENT COMPARISON ARTHRITIS TREATMENT COMPARISON GENERIC OA of (BRAND) HOW SUPPLIED AS GA JIA JRA OA Knee PsA RA CHELATING AGENTS Penicillamine Cap: 250mg ✓ (Cuprimine) Penicillamine Tab: 250mg ✓ (Depen) CYCLIC POLYPEPTIDE IMMUNOSUPPRESSANTS Cyclosporine Cap: 25mg, 100mg; ✓ (Gengraf, Neoral) Sol: 100mg/mL CYCLOOXYGENASE-2 INHIBITORS Celecoxib Cap: 50mg, 100mg, ✓ ✓ ✓ ✓ (Celebrex) 200mg, 400mg DIHYDROFOLIC ACID REDUCTASE INHIBITORS Methotrexate Inj: 25mg/mL; ✓ ✓ Tab: 2.5mg Methotrexate Tab: 5mg, 7.5mg, ✓ ✓ (Trexall) 10mg, 15mg INTERLEUKIN RECEPTOR ANTAGONISTS Anakinra Inj: 100mg/0.67mL ✓ (Kineret) Tocilizumab Inj: 20mg/mL, ✓ ✓ (Actemra) 162mg/0.9mL GOLD COMPOUNDS Auranofin Cap: 3mg ✓ (Ridaura) Gold sodium thiomalate Inj: 50mg/mL ✓ ✓ (Myochrysine) HYALURONAN AND DERIVATIVES Hyaluronan Inj: 30mg/2mL ✓ (Orthovisc) Sodium hyaluronate Inj: 1% ✓ (Euflexxa) Sodium hyaluronate Inj: 10mg/mL ✓ (Hyalgan) Sodium hyaluronate Inj: 2.5mL ✓ (Supartz) HYLAN POLYMERS Hylan G-F 20 Inj: 8mg/mL ✓ (Synvisc, Synvisc One) KINASE INHIBITORS Tofacitinib Tab: 5mg ✓ (Xeljanz) MONOCLONAL ANTIBODIES Ustekinumab Inj: 45mg/0.5mL, ✓ (Stelara) 90mg/mL MONOCLONAL ANTIBODIES/CD20-BLOCKERS Rituximab Inj: 100mg/10mL, ✓ (Rituxan) 500mg/50mL (Continued) ARTHRITIS TREATMENT COMPARISON GENERIC OA of (BRAND) HOW SUPPLIED AS GA JIA JRA OA Knee PsA RA MONOCLONAL ANTIBODIES/TNF-BLOCKERS Adalimumab Inj: 20mg/0.4mL, ✓ ✓ ✓ ✓ (Humira) 40mg/0.8mL Golimumab Inj: 50mg/0.5mL, ✓ ✓ ✓ (Simponi) 100mg/mL Infliximab Inj: 100mg ✓ ✓ ✓ (Remicade) NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
    [Show full text]
  • List of a FEW of MANY Aspirin-Like Or Herbal Supplement Products To
    1809 E 13th St. Suite 100 -300 Tulsa, OK 74104 (918)582-6800 MEDICATION AND PRODUCTS TO BE AVOIDED PRIOR TO SURGERY **Do not stop taking blood pressure, diabetic, or prescribed medications that are not blood thinners. You will be advised at your pre-op when to stop these medications prior to surgery. If you have any question as to whether it is safe to stop a medication, please check with the prescribing physician. Aspirin and other non-steroidal anti-inflammatory drugs (NSAID’s), such as Motrin are strong anti-coagulants which can cause bleeding problems in normal individuals. In addition to these Aspirin- like medications, Vitamins and many herbal supplements (such as Garlic, Ginkgo, Ginseng, Flaxseed, Ginger, Feverfew, Bilberry, Chamomile, Selenium) can cause bleeding or adverse physiologic effects during surgery. If you are on a blood thinner or antiplatelet medication such as Eliquis, Coumadin (warfarin), Plavix (clopidogrel), Pletal (cilostazol)Pradaxa or Xarelto, you must stop these medications prior to surgery. Please follow the prescribing physician’s recommendation for stopping the medications. Do not restart blood thinners until your physician advises. Patients preparing for surgery must stop all sources of Aspirin, Aspirin like products, Vitamins and all Herbal Supplements or Diet Pills for 7 days prior to surgery and 5 days after surgery. Below are a FEW OF MANY Aspirin-like or Herbal Supplement products to be avoided prior to surgery. Advil Congesprin Chewable Fish Oil Nabumetone Selenium Aggrenox Compounded Creams Flaxseed Nalfon Sine – Aid Aleve Contac Flurbiprofen Naprelan Sine – Off Sinus Alka – Seltzers Cope Four Way Cold Tabs Naprosyn Sinutab Anacin Coricidin Gaysal-S Naproxen SK – 65 Anaprox Cosprin Garlic (Allium Sativum) Neocylate Soma Anadynos Coumadin Gelprin Norgesic Stanback Ansaid Damason P Gemnisin Novnaproxen Stendin APC Darvon Ginger Novodipiradrol St.
    [Show full text]
  • S Salsalate Tablets
    SALSALATE TABLETS CARDIOVASCULAR EFFECTS renal disease. If SALSALATE TABLETS therapy must be initiated, Rx Only Cardiovascular Thrombotic Events close monitoring of the patient’s renal function is advisable. Cardiovascular Risk Clinical trials of several COX-2 selective and nonselective NSAIDs Anaphylactoid Reactions • NSAIDs may cause an increased risk of serious cardiovascular of up to three years duration have shown an increased risk of As with other NSAIDs, anaphylactoid reactions may occur in thrombotic events, myocardial infarction, and stroke, which can serious cardiovascular (CV) thrombotic events, myocardial patients without known prior exposure to SALSALATE TABLETS. be fatal. This risk may increase with duration of use. Patients infarction, and stroke, which can be fatal. All NSAIDs, both COX-2 SALSALATE TABLETS should not be given to patients with the with cardiovascular disease or risk factors for cardiovascular selective and nonselective, may have a similar risk. Patients with aspirin triad. This symptom complex typically occurs in asthmatic disease may be at greater risk. (See WARNINGS and CLINICAL known CV disease or risk factors for CV disease may be at greater patients who experience rhinitis with or without nasal polyps, or TRIALS). risk. To minimize the potential risk for an adverse CV event in who exhibit severe, potentially fatal bronchospasm after taking • SALSALATE TABLETS is contraindicated for the treatment of patients treated with an NSAID, the lowest effective dose should be aspirin or other NSAIDs (see CONTRAINDICATIONS and perioperative pain in the setting of coronary artery bypass graft used for the shortest duration possible. Physicians and patients PRECAUTIONS - Preexisting Asthma). Emergency help should be (CABG) surgery (see WARNINGS Gastrointestinal Risk) should remain alert for the development of such events, even in sought in cases where an anaphylactoid reaction occurs.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Effect of Targeting Inflammation with Salsalate
    Supplementary Online Content Hauser TH, Salastekar N, Schaefer EJ, et al; Effect of targeting inflammation with salsalate: the TINSAL-CVD randomized clinical trial on progression of coronary plaque in overweight and obese patients using statins. JAMA Cardiol. Published online May 25, 2016. doi:10.1001/jamacardio.2016.0605. eAppendix 1. Supplemental Background eAppendix 2. Additional TINSAL-CVD Study Team in Alphabetical Order Providing Current Contact Information eFigure. Coronary Artery Segment Plaque Assessment Demonstrating [A] Progression and [B] Regression Over 30-Months eTable 1. Primary Endpoint Plaque Volume in Salsalate Versus Placebo Results for the Intention to Treat (ITT) Population (Per Plaque Analysis) eTable 2. Secondary Analysis Plaque Density in Salsalate Versus Placebo Results for the Intention to Treat (ITT) Population (Per Plaque Analysis) eTable 3. Plaque Volume and Plaque Density in Salsalate Versus Placebo Results for the Intention to Treat (ITT) Population (Per Subject Analysis) eTable 4. Plaque Volume and Plaque Density in Salsalate Versus Placebo Results for the Per Protocol Analyses eTable 5. Plaque Volume and Plaque Density in Salsalate Versus Placebo Results for the Participants With Type 2 Diabetes eTable 6. Sensitivity Analyses Using Markov Chain Monte Carlo Method eTable 7. Baseline and Change From Baseline of Clinical and Laboratory Parameters by Treatment Group (SI Units) eTable 8. Serious Adverse Events Occurring After Randomization by Treatment Assignment eTable 9. Cardiac Events by Treatment Assignment eTable 10. Adverse Events Reported by 5% of Total Cohort and Numerically More in Salsalate Than Placebo Treated Group This supplementary material has been provided by the authors to give readers additional information about their work.
    [Show full text]
  • Multiple Targets of Salicylic Acid and Its Derivatives in Plants and Animals
    REVIEW published: 26 May 2016 doi: 10.3389/fimmu.2016.00206 Multiple Targets of Salicylic Acid and Its Derivatives in Plants and Animals Daniel F. Klessig1*, Miaoying Tian2 and Hyong Woo Choi1 1 Boyce Thompson Institute, Cornell University, Ithaca, NY, USA, 2 Department of Plant and Environmental Protection Sciences, University of Hawaii at Manoa, Honolulu, HI, USA Salicylic acid (SA) is a critical plant hormone that is involved in many processes, includ- ing seed germination, root initiation, stomatal closure, floral induction, thermogenesis, and response to abiotic and biotic stresses. Its central role in plant immunity, although extensively studied, is still only partially understood. Classical biochemical approaches and, more recently, genome-wide high-throughput screens have identified more than two dozen plant SA-binding proteins (SABPs), as well as multiple candidates that have yet to be characterized. Some of these proteins bind SA with high affinity, while the affinity of others exhibit is low. Given that SA levels vary greatly even within a particular plant species depending on subcellular location, tissue type, developmental stage, and with respect to both time and location after an environmental stimulus such as infection, the presence of SABPs exhibiting a wide range of affinities for SA may provide great Edited by: flexibility and multiple mechanisms through which SA can act. SA and its derivatives, Brigitte Mauch-Mani, Université de Neuchâtel, Switzerland both natural and synthetic, also have multiple targets in animals/humans. Interestingly, Reviewed by: many of these proteins, like their plant counterparts, are associated with immunity or Robin Katrina Cameron, disease development. Two recently identified SABPs, high mobility group box protein McMaster University, Canada and glyceraldehyde 3-phosphate dehydrogenase, are critical proteins that not only serve Taras P.
    [Show full text]
  • Nsaids: Friend Or Foe in the Battle Against Pain?
    NSAIDs: Friend or Foe in the Battle against Pain? Presented by June E. Oliver, MSN, CCNS, AP-PMN, APRN/CNS NO Conflicts of Interest to Declare Old & Natural! 1763 fever Rx- bark/leaves of willow/myrtle (salicylic acid) 1859-chemical structure discovered & synthesized in Germany 1914- Bayer Co. started manufacturing ASA Current sales 11 billion ( 2014) Early 20 th Century- NSAIDs discovered 1971- discovered mechanism of action of NSAIDs by John R. Vane 1990s-COX-2 isoenzyme successfully identified & cloned Current- script & OTC use = > 30 billion doses/yr of NSAIDs In US Numbers increase every year Prostaglandin (PG) Mechanism of Action Prostaglandins( PG) - lipids derived from acids: i.e. arachidonic (AA), lineolic, others PGs have Variety of functions Constitutive GI mucosal protection Kidney function Trauma response Cell membrane trauma- releases AA & COX enzyme converts to PGs inflammation Peripheral & central sensitization of nociceptors to mechanical & chemical stimuli Pyretic response PGs rise in CSF w/ pyrogen introduction Although not an NSAID, acetaminophen blocks brain PG synthetase (COX3 inhibition ) Cyclo-oxygenase (COX): “The Convertors” Cyclo-oxygenase 1&2 = isoenzymes that convert AA to PGs (i.e. prostacyclin, & thromboxanes) COX-1 Expressed regularly- provides gastric & duodenal mucosal protection Stimulates production mucin/bicarbonate/phospholipid that covers surface of stomach Enhances GI mucosal blood flow w/ local vasodilation Enhanced epithelial cell reproduction & migration towards lumen Can be induced
    [Show full text]
  • Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act
    Updated June 07, 2021 Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act Three categories of bulk drug substances: • Category 1: Bulk Drug Substances Under Evaluation • Category 2: Bulk Drug Substances that Raise Significant Safety Risks • Category 3: Bulk Drug Substances Nominated Without Adequate Support Updates to Categories of Substances Nominated for the 503B Bulk Drug Substances List1 • Add the following entry to category 2 due to serious safety concerns of mutagenicity, cytotoxicity, and possible carcinogenicity when quinacrine hydrochloride is used for intrauterine administration for non- surgical female sterilization: 2,3 o Quinacrine Hydrochloride for intrauterine administration • Revision to category 1 for clarity: o Modify the entry for “Quinacrine Hydrochloride” to “Quinacrine Hydrochloride (except for intrauterine administration).” • Revision to category 1 to correct a substance name error: o Correct the error in the substance name “DHEA (dehydroepiandosterone)” to “DHEA (dehydroepiandrosterone).” 1 For the purposes of the substance names in the categories, hydrated forms of the substance are included in the scope of the substance name. 2 Quinacrine HCl was previously reviewed in 2016 as part of FDA’s consideration of this bulk drug substance for inclusion on the 503A Bulks List. As part of this review, the Division of Bone, Reproductive and Urologic Products (DBRUP), now the Division of Urology, Obstetrics and Gynecology (DUOG), evaluated the nomination of quinacrine for intrauterine administration for non-surgical female sterilization and recommended that quinacrine should not be included on the 503A Bulks List for this use. This recommendation was based on the lack of information on efficacy comparable to other available methods of female sterilization and serious safety concerns of mutagenicity, cytotoxicity and possible carcinogenicity in use of quinacrine for this indication and route of administration.
    [Show full text]